T.Man Pharmaceutical PCL (BKK:TMAN)
10.80
-0.20 (-1.82%)
At close: Aug 10, 2026
T.Man Pharmaceutical PCL Ratios and Metrics
Market cap in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,320 | 4,120 | 5,880 | - | - | - | |
Market Cap Growth | -11.48% | -29.93% | - | - | - | - |
Enterprise Value | 4,325 | 4,437 | 6,072 | - | - | - |
Last Close Price | 10.80 | 10.03 | 13.78 | - | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 8.32 | 7.88 | 13.05 | - | - | - |
Forward PE | 8.36 | 8.08 | 11.42 | - | - | - |
PS Ratio | 1.69 | 1.63 | 2.64 | - | - | - |
PB Ratio | 1.94 | 1.95 | 3.32 | - | - | - |
P/TBV Ratio | 1.98 | 1.99 | 3.39 | - | - | - |
P/FCF Ratio | 53.98 | 37.46 | 17.01 | - | - | - |
P/OCF Ratio | 11.44 | 12.25 | 11.32 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.69 | 1.76 | 2.73 | - | - | - |
EV/EBITDA Ratio | 6.10 | 6.33 | 9.41 | - | - | - |
EV/EBIT Ratio | 7.52 | 7.59 | 11.04 | - | - | - |
EV/FCF Ratio | 54.03 | 40.33 | 17.56 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.41 | 0.45 | 0.65 | 0.39 | 0.61 | 1.17 |
Debt / EBITDA Ratio | 1.30 | 1.33 | 1.76 | 0.95 | 0.94 | 4.43 |
Debt / FCF Ratio | 11.50 | 8.58 | 3.33 | 9.52 | 2.21 | 3.41 |
Net Debt / Equity Ratio | 0.00 | 0.09 | 0.20 | 0.16 | 0.32 | 1.13 |
Net Debt / EBITDA Ratio | 0.01 | 0.27 | 0.55 | 0.40 | 0.49 | 4.37 |
Net Debt / FCF Ratio | 0.06 | 1.74 | 1.02 | 3.92 | 1.15 | 3.30 |
Asset Turnover | 0.69 | 0.70 | 0.73 | 0.81 | 1.06 | 0.80 |
Inventory Turnover | 2.38 | 2.32 | 2.21 | 2.39 | 2.77 | 2.39 |
Quick Ratio | 1.20 | 1.15 | 0.90 | 0.94 | 0.76 | 0.34 |
Current Ratio | 1.62 | 1.55 | 1.24 | 1.42 | 1.12 | 0.69 |
Return on Equity (ROE) | 25.02% | 26.91% | 27.40% | 33.66% | 58.57% | 10.38% |
Return on Assets (ROA) | 9.74% | 10.10% | 11.30% | 13.38% | 19.82% | 3.21% |
Return on Invested Capital (ROIC) | 21.48% | 22.49% | 24.02% | 28.29% | 37.49% | 4.81% |
Return on Capital Employed (ROCE) | 24.50% | 26.20% | 29.30% | 32.70% | 51.60% | 12.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 11.94% | 12.70% | 7.66% | - | - | - |
FCF Yield | 1.85% | 2.67% | 5.88% | - | - | - |
Dividend Yield | 5.82% | 5.58% | 1.45% | - | - | - |
Payout Ratio | 34.11% | 33.63% | 296.35% | 2.74% | - | - |
Buyback Yield / Dilution | -9.46% | -16.47% | -24.68% | -10.30% | -246.21% | -8.20% |
Total Shareholder Return | -3.64% | -10.88% | -23.23% | -10.30% | -246.21% | -8.20% |